
PROVIDENCE THERAPEUTICS COMPANY BIO:

Providence Therapeutics is a private Biotechnology company that specializes in messenger RNA (mRNA) vaccine therapies. With extensive expertise in the science of mRNA, Providence started initially with oncology research and Cancer therapies. However, given the global COVID-19 crisis, we have temporarily pivoted from our original mission and is currently devoting our energy, knowledge, and resources to creating a world-class mRNA COVID-19 vaccine. It is our hope to serve the needs of Canada and other countries, to supply a COVID-19 vaccine solution, in addition to where there is an opportunity to apply mRNA technology to other cancers, therapies and infectious diseases.

Our first fully Made-In-Canada mRNA vaccine, PTX-COVID19-B, began Phase 1 human trials in February 2021. Please see link below for the May 12th, 2021 press release of our favorable Phase 1 clinical results:

[Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19](#)

Providence is excited to present at Alberta's Life Science Showcase to discuss our part, as well as collaboration with key partners, in building a future foundation for Alberta's biotech sector.

For further inquiries, please contact:

Noy Wong

Providence Therapeutics Holdings Inc.

Email: noy.wong@providencetherapeutics.com

Phone: (403) 265 - 3765